Blood test trial offers ‘exciting new era in cancer detection'
Speaking at an event to mark the renaming of a cancer lab in memory of the late Dame Deborah James, Mr Streeting said the work will help to bring England's cancer survival rates 'back up to some of the best in the world'.
April is #BowelCancer Awareness Month
Do you know the symptoms of bowel cancer?
It is important to see your doctor if you have any symptoms of bowel cancer for 3 weeks or more.
Learn more: https://t.co/HygGvX9AfE pic.twitter.com/R0WSyt0suL
— CPFT (@CPFT_NHS) April 22, 2025
'Dame Deborah James dedicated her life to raising awareness for cancer and finding ways that we can beat it, so it is only right that we honour her legacy by investing in research to help stop one of the country's biggest killers,' Mr Streeting said.
Dame Deborah died of bowel cancer aged 40 in 2022.
Officials from the Department of Health and Social Care (DHSC) said that the Bowelbabe Laboratory at the Francis Crick Institute in London, which is funded by Cancer Research UK, will bring together leading scientists and will conduct 'cutting-edge' research.
The department also said that patients, including those with bowel cancer, could soon benefit from the test.
The miONCO-Dx blood test could lead to more cancers being detected at an earlier stage, which means treatments will be more effective, officials added.
The technology, made by biotechnology company Xgenera, was developed alongside scientists from the University of Southampton.
It works by examining the microRNA in a blood sample and uses AI to identify if cancer is present and if so, where it is located in the body.
Initial tests show the blood test can detect up to 12 common cancers – including lung, gastric, prostate, oesophageal, liver, bladder, ovarian, bowel, pancreatic and breast cancers as well as bone and soft tissue sarcoma and a type of brain tumour – and has high sensitivity, with 99% accuracy.
It was developed using data from 20,000 patients.
The technology is to be trialled in 8,000 patients thanks to a £2.4 million grant though the National Institute for Health and Care Research (NIHR) and the Government.
The DHSC said that the development of the test has moved onto the next phase, the 'verification and validation phase', which will look at collating evidence to support the approval of the test for use in the NHS.
Mr Streeting, who had cancer himself in 2021, added: 'We know that the key to surviving cancer is catching it as early as possible, so this government is taking the urgent action needed to make sure that happens through our plan for change, from developing world-leading technology to detect bowel cancer earlier, through to setting up hubs for the UK's top scientists to research and treat the disease.
'And research is only one part of the work we're doing. Our national cancer plan will transform cancer so patients can get the latest treatments and technology, ultimately bringing this country's cancer survival rates back up to some of the best in the world.'
Professor Lucy Chappell, chief scientific adviser at the DHSC and chief executive of the NIHR, added: 'Innovations such as the miONCO-Dx blood test offer an exciting new era in cancer detection with the potential for quicker, easier and more effective ways to detect cancers before they become more difficult to treat.'
Professor Sir Stephen Powis, NHS England's national medical director, said: 'This blood test has the potential to help us detect bowel cancer earlier and reduce the need for invasive tests, and the next step in this trial will now be vital in gathering further evidence on its effectiveness and how it could work in practice.
'Dame Deborah James was a tireless and inspirational campaigner who helped change the national conversation on bowel cancer – it's fitting that this lab in her name will drive forward research that could help thousands more people survive the disease.'
Michelle Mitchell, chief executive of Cancer Research UK, added: 'Bowel cancer is the second biggest cause of cancer deaths in the UK. I'm delighted to welcome the Health Secretary, Wes Streeting, to the Bowelbabe Laboratory and show him the cutting-edge research being carried out in the name of the inspirational Dame Deborah James. She touched the lives of so many, and her legacy is supporting people affected by bowel cancer across the country.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
7 minutes ago
- Powys County Times
Alzheimer's blood test ‘can accurately pick up early symptoms'
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
The Independent
13 minutes ago
- The Independent
NHS body revokes guidance advising hospitals to allow trans people to use chosen bathrooms
An NHS body has been criticised after it quietly withdrew guidance advising hospitals to allow trans people to use bathrooms and changing rooms of their choice. The NHS Confederation - which represents NHS trusts across the UK - confirmed to The Independent that it had removed the guidance from its website as it became 'dated' after April's Supreme Court ruling. The judgment found that the terms 'woman' and 'sex' in the Equality Act refer to a biological woman and biological sex, sparking disputes on how Britain should treat its equality policy. In the weeks after the ruling, the Equality and Human Rights Commission (EHRC) issued interim guidance which stated that trans women 'should not be permitted to use the women's facilities' in workplaces or public-facing services such as shops and hospitals'. The guidance is being legally challenged by trans-rights groups. The NHS Confederation said it had withdrawn its previously trans-inclusive advice and will issue new guidance when the EHRC updates its official Code of Practice. But trans rights groups have warned guidance on access to single-sex spaces is currently a legal 'minefield'. "The Supreme Court decision about the Equality Act doesn't mention toilets - not even once - and their provision is governed by separate legislation,' founder and executive director of Good Law Project, Jo Maugham KC, told The Independent. 'What the Supreme Court was very careful to say is that its judgment about the meaning of "woman" was solely about that word in the Equality Act. The 'toilets question' will be determined in judicial review proceedings that Good Law Project is filing today. 'For the NHS (or any other service provider) to take a position before the outcome is known is to invite lawsuits against it and risk wasting money that ought to be spent on patient care in the pursuit of ill-advised culture wars." TransActual, an organisation that supports the rights of trans people, said the development highlights the confusing implications of the ruling. "This decision may - or may not - be required as a result of the recent Supreme Court ruling,' a spokesperson said. 'However, what appears abundantly clear, based on advice from multiple lawyers and experts in this field, is that the supposed 'clarity' welcomed by the prime minister shortly after the ruling is, itself, in need of some clarification. "The law, based on a narrow interpretation of the Equality Act, may support this action. Equally, any future challenges on human rights grounds, which were not considered by the Supreme Court, may lead to a different outcome. It is a minefield. Organisations are damned if they act; damned if they do not. "We sympathise with the NHS Confederation and the position they find themselves in. Nonetheless, we believe they have reached the wrong conclusion - and that will, in turn, lead to significant harm to trans people needing medical care, as they now put off, or refuse treatment that may require a hospital stay." The NHS Confederation - which does not set official NHS policy - said its intention remains to provide its members with 'information that helps them best support their staff and patients', as it confirmed it had taken its previous guidance down. A spokesperson said: 'We will update and reinstate our guide as soon as the EHRC has updated its Code of Practice, which will need to be approved by the UK government, and when NHS England has then updated its guidance for what the changes mean for NHS organisations. 'The withdrawal of our guide does not change our explicit commitment to support our members to reduce the unacceptably high levels of bullying, abuse and discrimination at work that trans and non-binary staff and patients face.' On Monday, a hearing in a case against the EHRC over its consultation period for guidance in the wake of the Supreme Court ruling is set to go ahead. Human rights group Liberty is arguing the equalities watchdog had breached its statutory duties by implementing a six-week consultation period rather than a 12-week one. The EHRC will issue official post-ruling guidance after the consultation period.
Glasgow Times
20 minutes ago
- Glasgow Times
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'
